Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGY) saw a significant drop in short interest in March. As of March 13th, there was short interest totaling 3,903 shares, a drop of 87.6% from the February 26th total of 31,431 shares. Based on an average daily trading volume, of 149,464 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Lonza Group Trading Up 1.8%

LZAGY stock opened at $61.20 on Thursday. The firm has a 50 day simple moving average of $66.57 and a two-hundred day simple moving average of $67.52. Lonza Group has a one year low of $55.57 and a one year high of $73.85. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada raised Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Zacks Research lowered Lonza Group from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Lonza Group has a consensus rating of “Hold”.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.